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Desde a descoberta de Monastrol em 1999 como o primeiro inibidor de Eg5, 
diidropirimidinonas / thiones funcionalizadas (DHPMs) emergiram como protótipos para o 
desenvolvimento de drogas em diferentes alvos biológicos. O presente trabalho teve como 
objetivo avaliar a atividade antifúngica de DHPMs que foram obtidas empregando a reação 
de Biginelli. Suas atividades antifúngicas foram avaliadas contra C. neoformans e C. 
albicans. Os compostos 1-i e 1-k inibiram moderadamente o crescimento fúngico de C. 
neoformans, já o composto 2-k apresentou valores de MIC80 de 62,5-125 μg.mL
-1. 
Considerando a atividade contra C. albicans, os compostos 1-i e 1-n apresentaram um valor 
MIC50 de 125-250 μg.mL
-1. As mudanças realizadas no núcleo das DHPMs parecem ser 
valiosas para gerar compostos com potencial efeito antifúngico. 
 
Este manuscrito foi elaborado segundo as normas do “Letters in Drug Design & 
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In vitro antifungal activity of dihydropyrimidinones/thiones against Candida albicans and Cryptococcus 
neoformans 
 
Abstract: Since the Monastrol discovery in 1999 as the first inhibitor of Eg5, functionalized 
dihydropyrimidinones/thiones (DHPMs) have emerged as prototypes for drug design in different targets. The 
present work aimed to evaluate the antifungal activity of a chemical library of DHPMs which were obtained 
employing the Biginelli reaction. Their antifungal activities were assessed against C. neoformans and C. 
albicans. The compounds 1-i and 1-k inhibited moderately the fungal growth of C. neoformans, with compound 
2-k presenting MIC80 values of 62.5-125 μg∙mL
-1
. Considering activity against C. albicans, the compounds 1-i 
and 1-n present a MIC50 value of 125-250 μg∙mL
-1
. The changes performed in DHPM scaffold appear to be 
valuable for generating compounds with potential antifungal effect. 
 
Keywords: Biginelli reaction, Cryptococcus neoformans, Candida albicans, antifungal activity, structure 
activity relationship, multicomponent reaction. 
 
1. Introduction  
Dihydropyrimidinones/thiones (DHPMs) are a class of heterocyclic compounds with several 
pharmacological activities, being considered privileged structures due to its ability of interaction with different 
biological targets
 1
. Among their pharmacological effects, the anticancer, antihypertensive, anti-inflammatory, 
antimicrobial and antioxidant  activities were previously described 
2
. In relation to their antifungal properties, the 
importance of the DHPMs’ scaffold was pointed out in several investigations 
3-5
. This scaffold is obtained by a 
simple and straightforward procedure, identified as Biginelli reaction, which consists on a three-component 
condensation of an aldehyde, a β-ketoester and a (thio)urea. A large diversity of building blocks can be used in 
Biginelli reaction, such as 1,3-dicarbonyl compounds, substituted aldehydes and (thio)ureas   
6-8
.  
Nowadays, fungal infections have emerged as a big problem for the public health 
9-10
. Their incidence has 
increased dramatically in recent years and in spite of the several available antifungal drugs, they are not 
completely effective for their eradication 
11
. In addition, they all possess a certain degree of toxicity and quickly 
develop resistance due to the large-scale use 
12
. In this context, there is a special interest in screening different 
molecules for their antifungal effect in order to find new antifungal chemical structures alternatives to the 
existing ones.  
7 
 
In the present study, we have synthesized 32 DHPMs which were evaluated against Candida albicans and 





2. Results and Discussion 
 
2.1. Synthesis of dihydropyrimidinones/thiones 
The DHPMs 1a-p and 2a-p were prepared using a previously reported methodology (Scheme 1)
 
and 




2.2. Spectral analysis 
In 
1
H-NMR spectrum, one downfield broad singlet or duplet of the NH-1 hydrogen of the DHPM 
skeleton appeared around 7.70-9.35 or 9.10-10.55 ppm, and for NH-3 appeared around 5.50-7.95 or 7.60-9.80 
ppm in CDCl3 and DMSO-d6, respectively. Downfield signals of aromatic hydrogens produced the next group of 
signals. The benzylic hydrogen produced a signal among 5.00-5.40 ppm, while the singlet of allylic CH3 
appeared at 2.20 ppm. The signals of system H3CCH2 system appeared as a triplet and quartet, respectively at 
1.10 and 4.00 ppm. 
In 
13
C-NMR decoupled spectrum, the most representative signals were the methyl carbons at 14 and 18 
ppm, the methyne carbon at 54 ppm, and the methylene carbon at 60 ppm. The two carbon vinylic of DHPM ring 
appeared at about 105 and 146 ppm. The ester carbonylic carbon, produced a signal at 165 ppm, while the most 
downfield signals were appeared at 178 ppm corresponds to the quaternary carbon of C=S bond thionyl and near 
of 152 ppm corresponds to the quaternary carbon of C=O, which are situated between the two nitrogen. These 
assignments are represented in Figure 1. The spectra data of the most active compound (2-k) are described 
below, and the spectral characterization of others compounds are listed in supplementary material. 
 
Ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-k): yield 76%, mp 210-
212°C. 
1
H NMR (300 MHz, DMSO-d6): 1.11 (t, 3H, J = 7.1 Hz), 2.29 (s, 3H),  4.01 (q, 2H, J = 7.0 Hz), 5.30 (d, 
1H, J = 3.1 Hz), 7.53 (d, 2H, J = 8.6 Hz), 7.92 (s, 1H, NH), 8.23 (d, 2H, J = 8.7 Hz), 9.39 (s, 1H, NH). 
13
C NMR 





2.3. Antifungal activity 
In order to have a look into the pharmaceutical application of DHPMs as prototypes for the 
development of new antifungal drugs, the antifungal properties of 32 DHPMs (Table 1) against C. albicans and 
C. neoformans were explored. The selection of C. neoformans was due to the fact that this opportunistic fungus 
is the main cause of cryptococcal meningoencephalitis, which has a high incidence among HIV patients with 
impaired defenses 
16
. Even though new antifungal drugs have been developed in recent years, the availability of 
antifungal agents with anticryptococcal activity is still limited and sometimes the strains develop quickly 
resistance 
12-13, 17
. This scenario has motivated the search of new compounds that have antifungal properties 
against this fungus 
18
. 
In turn, C. albicans is the fourth leading cause of nosocomial bloodstream infection in intensive care 
units, causing fatal invasive candidiasis in a high percentage of patients. As a consequence, new anti-Candida 
structures are highly needed 
14
. 
Results were expressed as the percentage of inhibitions of the fungus displayed by each compound in 
the range 250–3.9 µg∙mL
-1
.They were determined by using the standardized microbroth dilution method M-
27A3 of the Clinical and Laboratory Standards Institute 
19
, that assures confident and reproducible results. Also 
the minimum concentration that inhibits either 80% (MIC80) or 50% of the fungal growth (MIC50) was assessed 
for each compound. 
For a better comprehension of the antifungal results, we grouped the compounds into two series: (I) 
dihydropyrimidin-2-thiones derivatives (1-a - 1-p) and (II) dihydropyrimidin-2-one derivatives (2-a - 2-p) that 
differ one each other in that (I) are thio-ketones and (2) are ketones that bear the same substituents in the 
aromatic ring for comparative purposes. They were tested against C. albicans ATCC 10231 and C. neoformans 
ATCC 32264 at concentrations from 250 to 3.9 µg.mL
-1
 and the percentages of inhibition of each compound at 
all concentrations were determined. These inhibition percentages can be seen in full in the Supplementary Table 
1 (Table S1). For the sake of clarity, Table S1 was summarized in Table 2 by recording the MICs at different 
endpoints such as MIC80 and MIC50 (minimum concentration at which each compound that inhibits 80% or 50% 
of the fungal cell growth that have showed to consistently represent the in vitro activity of compounds 
20
. 
From the analysis of Table 2, it is clear that all compounds displayed some degree of activity (MICs ≤ 
250 µg/mL) against C. albicans (lines in white) and C.  neoformans (lines highlighted in grey).  However,  C. 
neoformans  showed  to  be  more  sensitive  to  the  whole  series  than  C. albicans,  since  ten  compounds  (1c, 
1d, 1h-1l, 1n, 2h and 2k) showed  MIC50 ≤ 250 µg∙mL
-1
 against  C. neoformans while only tow (1n and 1i) 
showed marginal activity against C. albicans.  The same analysis can be performed with MIC80; for this 
9 
 
breakpoint, four compounds (1i, 1l, 1n and 2k) showed activity against C. neoformans while none showed 
activity against C. albicans. 
Regarding the difference in activity between series I and II against C. neoformans, Table 2 clearly 
shows that compounds of the series I, with a thio-ketone in their structures, displayed better activities than those 
of series II with a ketone, showing that the sulfur atom can have an important role in the activity. This is 
evidenced by the fact that eight compounds of series I (1c, 1d, 1h-1l and 1n)  showed MIC50 values ≤ 250 
µg∙mL
-1
 against C. neoformans, while among the compounds of series II, just two of them (2-h and 2-k) 
inhibited more than 50% of the C. neoformans growth. The same analysis can be made with MIC80: five 
compounds (1i-1l and 1n) showed antifungal activities in the series I while only one (2k) showed activity in the 
series II. Figures 2 and 3 clearly show the differences in activity of series I and II against C. neoformans. 
Within series I, it is worth to observe that most of active compounds against C. neoformans (1-h-1n, 
Figure 2) possess a substituent in the p-position of the aromatic ring and, the most active compound was 1h that 
possesses a CN- substituent in the p-position. 
To deepen the analysis of the compounds with antifungal activities, the LogP of each compound (1a-
1p; 2a-2p) was analyzed.  It is known that LogP (logarithm of the partition coefficient in a biphasic system, e.g. 
n-octanol/water) describes the macroscopic hydrophobicity of a molecule which is a factor  that  many  times  
determines  its  ability  to  penetrate  the membranes of fungal cells and to reach the interacting sites, thus 
influencing the antifungal activity of compounds 
21
.   
In Table 3, the LogP were recorded and in Figure 4 the correlation with the antifungal activity can be 
observed. The rule-of-five comprises four physicochemical parameters that can predict whether the molecules 
will be orally active or not. It is worth to take into account that 90% of orally active medicines, which are on 
clinical phase II, follow this rule. The four physicochemical parameters are Log P ≤ 5, H-bond acceptors ≤ 10, 
molecular weight ≤ 500 and H-bond donors ≤ 5 
22
. The 32 DHPMs tested against C. neoformans and C. albicans 
yeasts fit on these four parameters (Table 3) presenting a high probability of these compounds to be developed as 
a drug. 
In Figure 4, it can be observed that the most active compounds [those with inhibition percentages of  60 
% (right and up quarter)] have LogP higher than 1 and, mostly, higher than 1.5. Instead, most compounds that 
have low (< 50%) growth inhibition percentages (left and down quarter) belong to series II, with LogP values 
were lower than 1. Thus, in the results reported here, were identified that the para-substituent in the aromatic 
ring with a LogP value higher than 1.00 can improve the activity.  
10 
 
It is important to consider the relevance of the toxicity of these molecules to be a promising candidate 
for pharmaceutical development, because the compound not only should be effective against fungi but also 
should have good pharmacokinetics and not be toxic for healthy cells. Considering this point, a pre-clinical study 
with 1-e  compound, with in vitro effect against glioma cell line 
23
, was performed in rats and it demonstrated 
that it has appropriate bioavailability, linear pharmacokinetics and no acute toxicological effects after oral 
administration 
24
, showing that DHPMs could be the prototype of a new medicine.   
There are previous promising studies approaching DHPMs derivatives against C. albicans showing 








, and zones of inhibition of 17 mm 
4
. However, the data reported in 
this paper are the first pharmacological screening of DPHM against C. neoformans.   
 
3. Materials and Methods 
 
3.1. Chemistry 
The compounds 1-a-1-p and 2-a-2-p were synthetized through a Biginelli reaction promoted by 
triethylorthoformate as described elsewhere 
15
. A mixture of ethyl acetoacetate (1eq), aromatic aldehyde (1eq), 
(thio)ureas (2eq), citric acid (10 mol %) and triethylorthoformate (2eq) were placed in a round bottom flask and 
heated under stirring in a pre-heated oil batch (100 °C). The reactions were monitored by TLC, and stopped by 
addition of water and the crude mixture was cooled in an ice-bath under vigorous stirrer. The solid that was 
formed was filtered, washed with small portions of cold ethanol and then, dried under vacuum to afford the 
desired product with good purity grade. The LogP value was calculated by ChemDraw Ultra 12.0 (2010, 
CambridgeSoft).  




C NMR) were recorded in an Bruker Ascend, Varian 
INOVA-300 spectrometer or Brucker Avance DPX-250 NMR spectrometer with standard pulse sequences 
operating at 400 MHz, 300 MHz or 250 MHz for 1H NMR and 100MHz, 75 MHz or 62.5 MHz for 13C NMR, 
respectively, using DMSO-d6 or CDCl3 as solvent. Chemical shifts are reported as d values (ppm) relative to 
TMS (0.0 ppm). The NMR multiplicities br s, s, d, t, q, and m stand for broad singlet, singlet, doublet, triplet, 
quartet and multiplet, respectively. TLC analyses were performed on Merck´s silica plates 60 F254. Melting-
points (mp) were determined on a System Kofler type WME apparatus and are uncorrected. The term room 
temperature means 20-30ºC. All products were identified through their spectroscopic dada and the melting-




3.2. Antifungal assays 
3.2.1. Microorganisms and media 
For the antifungal evaluation, strains from the American Type Culture Collection (ATCC), Rockville, 
MD, USA, C. albicans ATCC 10231 and C. neoformans ATCC 32264 were used, Strains were grown on 
Sabouraud-chloramphenicol agar slants for 48 h at 30 °C, maintained on slopes of Sabouraud-dextrose agar 
(SDA, Oxoid) and sub-cultured every 15 days to prevent pleomorphic transformations. Inocula were obtained 
according to reported procedures 
19
 and adjusted to 1-5∙10
3 
cells with colony forming units (CFU)/mL. 
 
3.2.2. Fungal Growth Inhibition Percentage Determination.  




were performed in 96-well microplates. For 
the assay, compound test-wells (CTWs) were prepared with stock solutions of each compound in DMSO 
(maximum concentration ≤ 1%), diluted with RPMI-1640, to final concentrations of 250-3.9 μg∙mL
-1
. An 
inoculum suspension (100 μL) was added to each well (final volume in the well = 200 μL). A growth control 
well (GCW) (containing medium, inoculum, and the same amount of DMSO used in a CTW, but compound-
free) and a sterility control-well (SCW) (sample, medium, and sterile water instead of inoculum) were included 
for each fungus tested. Microtiter trays were incubated in a moist, dark chamber at 30 °C for 48 h for both 
yeasts. Microplates were read in a VERSA Max microplate reader (Molecular Devices, Sunnyvale, CA, USA). 
Amphotericin B (Sigma Aldrich, St Louis, MO, USA) was used as positive control. Tests were performed in 
triplicate. Reduction of growth for each compound concentration was calculated as follows: % of inhibition = 
100 - (OD 405 CTW − OD 405 SCW)/(OD 405 GCW − OD 405 SCW). The means ± SD (standard deviations) 
were used for constructing the dose-response curves representing % inhibition vs concentration of each 
compound.  
 
3.2.3. MIC80 and MIC50 determinations 
Two endpoints were defined from the dose-response curves. Minimum inhibitory concentrations 
resulting in 80 or 50 % of the fungal growth respectively were named MIC80 and MIC50.  
 
3.2.4. Statistical Analysis. 






Two series of DHPMs were prepared and their activities against C. albicans and C. neoformans were 
assessed. Furthermore, compounds with a substituent in the p-position of the aromatic ring showed promising 
activities mainly against C. neoformans. The data reported here, showed that the presence of thio-ketone in 
dihydropirymidinic ring can be an important role in antifungal effect. Moreover, the most active structures 
possess LogP between 1 and 2.5, while the less active molecules possess LogP values lower than 1.  
In addition, the values for the four physicochemical parameters LogP ≤ 5, molecular weight ≤ 500, H-
bond acceptors and H-bond donors ≤ 10, and ≤ 5 that can predict if the molecules will be orally active, were 
fulfilled for the active molecules, thus appearing DHPMs good candidates for pharmaceutical development.  
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Scheme 1 – Synthesis of DHPM’s 
 
 
Fig1- General features of ¹H NMR (A) and ¹³C NMR (B) of synthetized DHPM’s. 
 




Fig3- Antifungal activity of dihydropyrimidin-2-ones 2-a-2-p (series II) against C. neoformans. 
 
Fig4- Relationship between LogP and % inhibition at 250 µg∙mL
-1


























































































Table 2: The 80% and 50% inhibitory concentrations (MIC80 and MIC50) of 1a-p and 2a-p 
against Candida albicans (Ca) ATCC 10231 and Cryptococcus neoformans (Cn) ATCC 32264.  







N° type R1 R2 R3 fungi MIC80 MIC50 N° type R1 R2 R3 fungi MIC80 MIC50 
1-a A H H H 
Ca >250 >250 
2-a C H H H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-b A H H F 
Ca >250 >250 
2-b C H H F 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-c A H H OCH3 
Ca >250 >250 
2-c C H H 
OCH
3 
Ca >250 >250 
Cn >250 250 Cn >250 >250 
1-d A H H NO2 
Ca >250 >250 
2-d C H H NO2 
Ca >250 >250 
Cn >250 125 Cn >250 >250 
1-e A H NO2 H 
Ca >250 >250 
2-e C H NO2 H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-f A H OH H 
Ca >250 >250 
2-f C H OH H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-g A H OCH3 H 
Ca >250 >250 
2-g C H OCH3 H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-h A CN H H 
Ca >250 >250 
2-h C CN H H 
Ca >250 >250 
Cn >250 31.2 Cn >250 250 
1-i A F H H 
Ca >250 250 
2-i C F H H 
Ca >250 >250 
Cn 125 125 Cn >250 >250 
1-j A N(CH3)2 H H 
Ca >250 >250 
2-j C N(CH3)2 H H 
Ca >250 >250 
Cn >250 250 Cn >250 >250 
1-k A NO2 H H 
Ca >250 >250 
2-k C NO2 H H 
Ca >250 >250 
Cn >250 125 Cn 125 31.2 
1-l A OCH3 H H 
Ca >250 >250 
2-l C OCH3 H H 
Ca >250 >250 
Cn 250 250 Cn >250 >250 
1-m A OCH3 OCH3 H 
Ca >250 >250 
2-m C OCH3 OCH3 H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-n A -OCH2O- H 
Ca >250 250 
2-n C -OCH2O- H 
Ca >250 >250 
Cn 250 250 Cn >250 >250 
1-o A OH OCH3 H 
Ca >250 >250 
2-o C OH OCH3 H 
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
1-p B  
Ca >250 >250 
2-p D  
Ca >250 >250 
Cn >250 >250 Cn >250 >250 
Amphotericin B 
Ca 1.00 0.78 
 
Cn 0.50 0.25 
19 
 
Table 3 - Chemical features of compounds 
 M.W. Donor Acceptor  LogP  M.W. Donor Acceptor  LogP 
1-a 276.09 2 1 1.96 2-a 260.29 2 2 0.54 
1-b 294.43 2 1 2.12 2-b 278.28 2 2 0.69 
1-c 306.38 2 2 1.84 2-c 290.31 2 3 0.41 
1-d 321.35 2 3 1.58 2-d 305.29 2 4 1.07 
1-e 321.35 2 3 1.58 2-e 305.29 2 4 1.07 
1-f 292.35 3 2 1.57 2-f 276.29 3 3 0.15 
1-g 306.38 2 2 1.84 2-g 290.31 2 4 0.41 
1-h 301.36 2 2 2.00 2-h 285.30 2 3 0.57 
1-i 294.43 2 1 2.12 2-i 278.28 2 2 0.69 
1-j 319.42 2 2 2.25 2-j 303.16 2 3 0.82 
1-k 321.35 2 3 1.58 2-k 305.29 2 4 1.07 
1-l 306.38 2 2 1.84 2-l 290.31 2 3 0.41 
1-m 336.41 2 3 1.71 2-m 320.34 2 4 0.22 
1-n 320.36 2 3 1.74 2-n 304.30 2 4 0.31 
1-o 322.38 3 3 1.45 2-o 306.31 3 4 0.02 
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Supplementary material (Antifungal Assays) 
Table 1Table 1S: Inhibition percentages (%) of Candida albicans (Ca) ATCC 10231 and Cryptococcus .neoformans (Cn) ATCC 
32264 by the compounds 1-a-1-p and 2-a-2-p. 
 
Comp Structure Fungi 250 μg/mL 125  μg/mL 62.5 μg.mL 31.2 μg.mL 15.6 μg.mL 7.81μg/mL 3.9 μg/mL 
1-a 
 
Ca 0 0 0 0 0 0 0 
Cn 25.59±0.68 23.25±4.45 20.58±3.06 0 0 0 0 
1-b 
 
Ca 0 0 0 0 0 0 0 
Cn 16.93±1.03 15.33±1.80 15.47±3.38 14.04±6.79 12.76±1.41 12.24±3.98 10.02±1.27 
1-c 
 
Ca 0 0 0 0 0 0 0 
Cn 44.82±1.37 44.53±1.03 37.00±8.57 25.56±9.95 19.93±9.56 0 0 
1-d 
 
Ca 6.53±0.67 6.40±1.73 5.49±1.03 4.30±1.14 2.23±0.15 3.54±1.56 1.33±0.25 
Cn 57.28±1.10 48.24±2.20 47.44±1.34 47.45±6.53 36.49±0.46 32.51±2.12 22.37±2.41 
1-e 
 
Ca 27.00±2.88 21.16±7.23 18.00±0.70 12.60±3.67 7.54±2.90 0 0 
Cn 27.00±2.88 21.16±7.23 18.00±0.70 12.60±3.67 7.54±2.90 0 0 
1-f 
 
Ca 0 0 0 0 0 0 0 
Cn 26.91±3.36 18.50±5.42 15.14±2.08 19.70±0.67 6.00±2.76 0 0 
1-g 
 
Ca 2.27±1.46 1.30±0.34 0 0 0 0 0 






Ca 19.96±1.04 1.78±0.95 1.27±0.40 0 0 0 0 





Ca 51.23±1.60 19.78±1.32 6.32±1.03 0.77±0.29 0 0 0 
Cn 78.72±0.72 76.81±1.72 33.76±5.32 29.16±3.27 9.51±0.18 0 0 
1-j 
 
Ca 41.85±2.62 37.28±1.09 6.80±3.07 1.92±0.45 0 0 0 
Cn 68.33±1.83 35.39±4.70 31.20±0.43 19.09±0.67 3.89±2.76 6.03±0.94 0 
1-k 
 
Ca 39.84±3.57 9.11±2.81 4.05±2.22 3.84±0.38 2.21±0.29 0 0 
Cn 69.77±7.69 54.64±3.36 0 0 0 0 0 
1-l 
 
Ca 42.13±5.24 16.61±0.11 0 0 0 0 0 




Ca 0 0 0 0 0 0 0 
Cn 24.92±5.87 23.84±6.15 21.92±4.23 19.15±1.07 13.42±5.42 19.13±1.04 0 
1-n 
 
Ca 51.56±5.79 30.09±1.29 6.22±1.10 2.81±1.01 0 0 0 
Cn 85.13±1.63 39.30±1.68 24.10±1.64 22.10±4.55 21.13±2.04 16.73±1.06 11.77±2.14 
1-o 
 
Ca 0 0 0 0 0 0 0 
Cn 35.52±4.58 21.16±2.12 3.50±0.63 3.20±0.37 0 0 0 
1-p 
 
Ca 7.10±5.10 4.33±2.68 3.10±0.35 2.58±0.58 1.86±0.89 0 0 
Cn 30.01±2.06 12.47±1.10 10.27±0.04 9.20±0.77 7.96±0.95 2.84±0.32 2.02±1.38 
2-a 
 
Ca 2.29±0.35 0 0 0 0 0 0 
Cn 36.63±5.82 34.99±3.72 26.82±0.67 16.52±0.69 4.27±0.54 7.41±0.90 0 
2-b 
 
Ca 0 0 0 0 0 0 0 





Ca 0 0 0 0 0 0 0 
Cn 15.80±3.53 14.84±7.10 5.69±3.50 0 0 0 0 
2-d 
 
Ca 5.29±2.97 4.21±0.01 3.65±2.81 0 0 0 0 
Cn 30.11±0.74 25.02±2.23 23.01±0.76 16.18±0.82 10.03±2.08 0 0 
2-e 
 
Ca 3.32±0.49 2.12±0.49 1.52±0.83 1.47±0.25 0 0 0 
Cn 22.33±7.12 15.91±1.69 11.73±0.80 11.77±1.13 10.67±2.57 0 0 
2-f 
 
Ca 2.01±0.29 0 0 0 0 0 0 
Cn 25.86±2.37 22.63±1.93 20.24±3.85 20.35±4.69 7.58±2.94 0 0 
2-g 
 
Ca 3.26±1.27 3.02±1.72 2.79±0.12 2.57±0.48 1.47±1.02 0 0 
Cn 27.92±6.85 22.36±0.99 24.75±0.99 19.86±0.74 18.58±0.96 15.92±0.83 10.52±0.39 
2-h 
 
Ca 0 0 0 0 0 0 0 
Cn 55.05±2.73 43.16±3.44 38.33±2.43 37.88±1.75 36.56±1.70 20.03±0.47 0 
2-i 
 
Ca 0 0 0 0 0 0 0 
Cn 17.23±5.95 16.66±7.41 7.26±0.85 5.22±0.87 0 0 0 
2-j 
 
Ca 15.06±2.22 9.74±2.85 3.93±0.49 3.45±0.64 1.16±0.36 0 0 
Cn 34.85±2.04 33.27±0.86 31.69±1.47 21.32±4.16 15.41±1.62 13.30±3.85 4.32±0.65 
2-k 
 
Ca 4.86±0.57 1.42±0.22 1.38±1.24 0 0 0 0 















Ca 0 0 0 0 0 0 0 
Cn 33.33±1.66 26.23±2.68 22.02±4.35 20.75±0.25 21.94±1.49 15.66±6.21 1.24±0.97 
2-m 
 
Ca 0 0 0 0 0 0 0 
Cn 37.06±6.36 35.14±0.30 27.96±2.83 27.29±0.62 20.31±3.46 19.73±6.63 0 
2-n 
 
Ca 5.80±0.48 4.36±0.56 2.22±0.54 2.02±0.42 1.53±0.31 0 0 
Cn 42.99±0.61 40.14±1.96 37.00±1.25 36.06±0.68 32.07±7.57 5.40±1.46 0 
2-o 
 
Ca 3.31±0.88 3.24±1.83 1.39±0.99 0 0 0 0 
Cn 27.82±0.72 26.85±2.52 20.30±3.11 19.20±2.73 16.11±3.65 0 0 
2-p 
 
Ca 7.31±0.53 7.75±2.95 2.64±0.27 0 0 0 0 
Cn 16.08±5.12 14.32±1.69 14.72±0.01 8.58±2.41 8.14±4.93 7.18±5.26 0 
Amphotericin B 
Ca 100 100 100 100 100 100 100 




Supplementary material (Spectra Data) 
Ethyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-a): yield 
92%; mp 204-207 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.09 (t, 3H, J=7.0 Hz), 2.29 (s, 3H), 
4.00 (q, 2H, J 7.0 Hz), 5.17 (d, 1H, J 3.7 Hz), 7.23-7.37 (m, 5H), 9.65 (d, 1H, J 3.8 Hz, NH), 
10.34 (br s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 14.1, 17.2, 54.1, 59.9, 100.7, 126.4, 
127.7, 128.6, 143.5, 145.1, 165.1, 174.2. 
 
Ethyl 4-(2-fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-b): 
yield 77%; mp 140-143 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.03 (t, 3H, J 7.0 Hz), 2.30 (s, 
3H), 3.93 (q, 2H, J 7.0 Hz), 5.45 (d, 1H, J 3.1 Hz), 7.13-7.34 (m, 4H), 9.59 (s, 1H, NH), 10.37 
(s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 14.5, 17.8, 49.4, 60.2, 100.0, 116.1, 116.4, 
125.3, 129.9, 130.5, 131.27, 146.1, 165.5, 174.7. 
 
Ethyl 6-methyl-4-(3-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-e): 
yield 97%; mp 206-209 ºC. 
1
H NMR (250 MHz, DMSO-d6): 1.13 (t, 3H, J 7.1 Hz), 2.34 (s, 
3H), 4.05 (q, 2H, J 7.1 Hz), 5.36 (d, 1H, J 3.6 Hz), 7.70-7.72 (m, 2H), 8.10- 8.11 (m, 1H), 
8.17-8.20 (m, 1H), 9.81 (br s, 1H, NH), 10.55 (br s, 1H, NH). 
13
C NMR (62.5 MHz, DMSO-
d6): 14.0, 17.3, 53.5, 59.8, 99.8, 121.2, 122.8,130.5, 133.0, 145.5, 146.0, 147.8, 164.9, 174.5. 
 
Ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-
f): yield 88%; mp 184-187 ºC. 
1
H NMR (250 MHz, DMSO-d6): 1.14 (t, 3H, J 7.1 Hz), 2.30 (s, 
3H), 4.04 (q, 2H, J 7.1 Hz), 5.11 (d, 1H, J 3.7 Hz), 6.65-6.69 (m, 3H), 7.10-7.18 (m, 1H), 9.46 
(s, 1H, OH), 9.62 (br s, 1H, NH), 10.31 (br s, 1H, NH); 
13
C NMR (62.5 MHz, DMSO-d6): 





g): yield 93%; 
1
H NMR (400 MHz, CDCl3): 1.17 (t, 3H, J 7.1 Hz), 2.34 (s, 3H), 3.78 (s, 3H), 
4.08 (m, 2H), 5.37 (d, 1H, J 2.6 Hz), 5.89 (br s, 1H, NH), 6.80 (m, 1H), 6.86 (m, 1H), 6.91 (d, 
1H, J 7.8 Hz), 7.24 (m, 1H), 8.14 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.1, 18.2, 
55.3, 56.0, 60.4, 102.7, 112.7, 112.7, 113.4, 119.0, 143.1, 143.8, 159.9, 165.3, 174.4. 
 
Ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-h): 
yield 80%; mp 130-133 °C. 
1
H NMR (300 MHz, DMSO-d6): 1.09 (t, 3H, J 7.0 Hz), 2.30 (s, 
3H), 4.00 (q, 2H, J 7.0 Hz), 5.24 (d, 1H, J 3.5 Hz), 7.40 (d, 2H, J 8.3 Hz), 7.83 (d, 2H, J 8.3 
Hz), 9.74 (br s, 1H, NH), 10.47 (br s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 14.0, 17.2, 
53.8, 59.8, 99.8, 127.5, 129.9, 132.7, 133.2, 138.8, 145.9, 148.5, 164.9, 174.5.  
 
Ethyl 4-(4-fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-i): 
yield 82%; 
1
H NMR (400 MHz, CDCl3): 1.31 (t, 3H, J 7.0 Hz), 2.32 (s, 3H), 4.05 (m, 2H), 
5.33 (s, 1H), 6.95 (d, 2H, J 8.3 Hz), 7.22 (d, 2H, J 6.2 Hz), 7.63 (br s, 1H, NH), 8.16 (br s, 1H, 
NH). 
13
C NMR (100 MHz, CDCl3): 14.1, 18.3, 55.5, 60.5, 102.9, 115.7 (d,
 2
J 21.6Hz), 128.6 
(d,
 3
J 8.3Hz), 138.3 (d,
 4
J 3.0Hz), 142.8, 162.6 (d,
 1
J 247.8), 165.1, 174.4.  
 
Ethyl 4-(4-(dimethylamino)phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-j): yield 82%; mp 206-208 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.11 (t, 3H, J 
7.0 Hz), 2.28 (s, 3H), 2.85 (s, 6H), 3.97 (q, 2H, J 7.0 Hz), 5.04 (d, 1H, J 3.2 Hz), 6.66 (d, 2H, 
J 8.5 Hz), 7.01 (d, 2H, J 8.5 Hz), 9.55 (br s, 1H, NH), 10.24 (br s, 1H, NH). 
13
C NMR (75 





Ethyl 6-methyl-4-(4-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-k): 
yield 74%. 
1
H NMR (400 MHz, CDCl3): 1.17 (t, 3H, J 7.1 Hz), 2.35 (s, 3H), 4.10 (q, 2H, J 7.1 
Hz), 5.50 (s, 1H), 7.24 (br s, 1H, NH), 7.45 (d, 2H, J 8.6 Hz), 7.76 (br s, 1H, NH), 8.15 (d, 
2H, J 6.41Hz). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.5, 53.4, 60.9, 102.1, 124.2, 127.7, 
143.6, 147.7, 148.9, 164.9, 174.9. 
 
Ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-
l): yield 85%. 
1
H NMR (400 MHz, CDCl3): 1.16 (t, 3H, J 7.1 Hz), 2.34 (s, 3H), 3.77 (s, 3H), 
4.08 (m, 2H), 5.33 (d, 1H, 3.0 Hz), 6.83 (m, 2H), 7.20 (m, 2H), 7.71 (br s, 1H, NH), 8.33 (br 
s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.1, 18.1, 55.3, 55.6, 60.3, 103.2, 114.2, 128.0, 
134.9, 142.5, 159.6, 165.3, 174.3. 
Ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(1-m): yield 92%. 
1
H NMR (400 MHz, CDCl3): 1.13 (t, 3H, J 7.1 Hz), 2.31 (s, 3H), 3.80 (s, 
6H), 4.05 (m, 2H), 5.30 (d, 1H, 2.9Hz), 6.76 (m, 3H), 7.76 (br s, 1H, NH), 8.32 (br s, 1H, 
NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.2, 55.8, 55.9, 56.0, 60.4, 103.1, 110.0, 111.3, 
119.0, 135.1, 142.6, 149.0, 149.1, 165.4, 174.2. 
  
Ethyl 4-(benzo[d][1,3]dioxol-5-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-n): yield 84%; mp 156-159 ºC. 
1
H NMR (250 MHz, DMSO-d6): 1.11 (t, 3H, J 
7.0 Hz), 2.28 (s, 3H), 3.99 (q, 2H, J 7.0 Hz), 5.08 (d, 1H, J 3.8 Hz), 5.99 (s, 2H), 6.64-6.72 
(m, 1H), 6.87 (m, 2H), 9.61 (br s, 1H, NH), 10.33 (br s, 1H, NH). 
13
C NMR (62.5 MHz, 
DMSO-d6): 14.1, 17.2, 53.6, 59.6, 100.6, 101.0, 106.7, 108.1, 119.6, 137.4, 145.0, 146.7, 
147.3, 165.0, 173.9. 
 
Ethyl 4-(4-hydroxy-3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-o): yield 54%. 
1
H NMR (400 MHz, CDCl3): 1.19 (t, 3H, J 7.1 Hz), 2.36 (s, 
27 
 
3H), 3.87 (s, 3H), 4.11 (m, 2H), 5.36 (d, 1H, 2.9 Hz), 6.79 (m, 2H), 6.85 (m, 1H), 7.19 (br s, 
1H, NH), 7.73 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.5, 56.0, 56.1, 60.5, 
103.2, 109.2, 114.6, 119.8, 134.5, 142.1, 145.8, 146.7, 165.3, 174.6. 
 
Ethyl 6-methyl-4-(thiophen-2-yl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-p): 
yield 51%. 
1
H NMR (400 MHz, CDCl3): 1.25 (t, 3H, J 7.1 Hz), 2.36 (s, 3H), 4.18 (m, 2H), 
5.69 (d, 1H, J 3.4Hz), 6.92 (m, 1H), 6.98 (m, 1H), 7.21 (m, 1H), 7.70 (br s, 1H, NH), 8.22 (br 
s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.3, 51.0, 60.6, 103.2, 124.8, 125.6, 126.9, 
143.3, 145.6, 165.0, 175.1. 
Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-a): yield 93%; 
mp 210-212 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.09 (t, 3H, J 7.1 Hz), 2.25 (s, 3H), 3.98 (q, 
2H, J 7.1 Hz), 5.15 (d, 1H, J 2.9 Hz), 7.22-7.32 (m, 5H), 7.74 (br s, 1H, NH), 9.20 (br s, 1H, 
NH). 
13
C NMR (75 MHz, DMSO-d6): 12.2, 16.0, 52.1, 57.3, 97.4, 124.4, 125.3, 126.4, 143.1, 
145.2, 150.2, 163.3.  
 
Ethyl 4-(2-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-b): 
yield 74%; mp 235-237 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.20 (t, 3H, J 7.1 Hz), 2.44 (s, 
3H), 4.07 (q, 2H, J 7.1 Hz), 5.62 (s, 1H), 7.28-7.48 (m, 4H), 7.87 (br s, 1H, NH), 9.43 (br s, 
1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 13.8, 17.5, 54.5, 61.1, 115.2, 122.4, 124.0, 127.8, 
129.3, 135.8, 154.7, 157.2, 158.3, 160.3. 
 
Ethyl 4-(2-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-c): 
yield 61%. 
1
H NMR (400 MHz, CDCl3): 1.09 (t, 3H, J 7.1 Hz), 2.43 (s, 3H), 3.88 (s, 3H), 
4.06 (m, 2H), 5.76 (d, 1H, 3.0 Hz), 6.89 (m, 2H), 7.03 (m, 1H), 7.27 (m, 1H), 7.43 (br s, 1H, 
NH), 8.22 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.5, 50.0, 55.3, 59.9, 98.4, 




Ethyl 6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-e): 
yield 92%; mp 225-227 ºC. 
1
H NMR (250 MHz, DMSO-d6): 1.08 (t, 3H, J 6.9 Hz), 2.26 (s, 
3H), 3.98 (q, 2H, J 6.9 Hz), 5.29 (s, 1H), 7.64-8.10 (m, 4H), 8.90 (s, 1H, NH), 9.37 (s, 1H, 
NH). 
13
C NMR (62.5 MHz, DMSO-d6): 14.0, 17.9, 53.6, 59.4, 98.4, 121.2, 122.3, 130.0, 
133.0, 147.0, 147.8, 149.3, 151.9, 165.0. 
 
Ethyl 4-(3-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-f): 
yield 87%; mp 163-166 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.11 (t, 3H, J 7.0 Hz), 2.22 (s, 
3H), 3.98 (q, 2H, J 7.0 Hz), 5.04 (s, 1H), 6.64-7.09 (m, 4H), 7.64 (s, 1H, NH), 9.15 (s, 1H, 
NH). 
13
C NMR (75 MHz, DMSO-d6): 14.2, 17.6, 52.9, 59.2, 100.1, 113.2, 114.9, 116.7, 
129.4, 147.0, 148.5, 152.2, 157.3, 165.9.  
 
Ethyl 4-(3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-g): 
yield 93%; 
1
H NMR (400 MHz, CDCl3): 1.18 (t, 3H, J 7.1 Hz), 2.35 (s, 3H), 3.79 (s, 3H), 
4.09 (m, 2H), 5.38 (s, 1H), 5.52 (br s, 1H, NH), 6.81 (dd, 1H, J 8.1, 1.9 Hz), 6.86 (s, 1H), 6.91 
(d, 1H, J 7.5 Hz), 7.23 (d, 1H, J 7.9 Hz), 7.35 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 
14.2, 18.7, 55.2, 56.6, 60.1, 101.2, 112.6, 112.9, 118.9, 129.8, 145.2, 146.4, 153.4, 159.8, 
165.6.  
 
Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-h): 
yield 86%; mp 130-133 °C. 
1
H NMR (300 MHz, DMSO-d6): 1.07 (t, 3H, J 7.1 Hz), 2.25 (s, 
3H), 3.97 (q, 2H, J 7.1 Hz), 5.21 (s, 1H), 7.42 (d, 2H, J 8.1 Hz), 7.80 (d, 2H, J 8.1 Hz), 7.88 
(s, 1H, NH), 9.33 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 14.5, 18.3, 54.3, 59.8, 98.7, 




Ethyl 4-(4-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-i): 
yield 89%; 
1
H NMR (400 MHz, CDCl3): 1.16 (t, 3H, J 7.1 Hz), 2.31 (s, 3H), 4.07 (m, 2H), 
5.36 (d, 2H, J 2.72 Hz), 6.29 (br s, 1H, NH), 6.98 (m, 2H), 7.26 (m, 2H), 8.65 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.6, 54.9, 60.1, 101.2, 115.5 (d,
 2





J 3.3Hz), 146.5, 153.8, 162.3 (d,
 1
J 246.5), 165.6.  
 
Ethyl 4-(4-(dimethylamino)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2-j): yield 75%; mp 257-259 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.05 (t, 3H, J 
7.0 Hz), 2.23 (s, 3H), 2.84 (s, 6H), 4.00 (q, 2H, J 7.0 Hz), 5.03 (d, 1H, J 3.1 Hz), 6.64 (d, 2H, 
J 8.5 Hz), 7.04 (d, 2H, J 8.5 Hz), 7.59 (br s, 1H, NH), 9.09 (br s, 1H, NH). 
13
C NMR (75 
MHz, DMSO-d6): 14.2, 17.7, 40.2, 53.3, 59.1, 99.9, 112.2, 126.9, 132.7, 147.6, 149.8, 152.3, 
165.5. 
 
Ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-k): 
yield 76%, mp 210-212°C. 
1
H NMR (300 MHz, DMSO-d6): 1.11 (t, 3H, J 7.1 Hz), 2.29 (s, 
3H),  4.01 (q, 2H, J 7.0 Hz), 5.30 (d, 1H, J 3.1 Hz), 7.53 (d, 2H, J 8.6 Hz), 7.92 (s, 1H, NH), 
8.23 (d, 2H, J 8.7 Hz), 9.39 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 14.1, 17.9, 53.7, 
59.4, 98.2, 123.9, 127.7, 146.7, 149.4, 151.8, 152.0, 165.1. 
 
Ethyl 4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-l): 
yield 91%. 
1
H NMR (400 MHz, CDCl3): 1.17 (t, 3H, J 7.1 Hz), 2.31 (s, 3H), 3.77 (s, 3H), 
4.07 (m, 2H), 5.33 (d, 1H, 1.6 Hz), 6.13 (br s, 1H, NH), 6.82 (m, 2H), 7.22 (m, 2H), 8.64 (br 
s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.5, 55.0, 55.3, 60.0, 101.5, 114.0, 127.8, 





(2-m): yield 83%. 
1
H NMR (400 MHz, CDCl3): 1.17 (t, 3H, J 7.1 Hz), 2.33 (s, 3H), 3.83 (s, 
3H), 3.84 (s, 3H), 4.09 (m, 2H), 5.35 (d, 1H, 2.6Hz), 6.02 (br s, 1H, NH), 6.79 (d, 1H, J 
8.8Hz), 6.85 (m, 2H), 8.35 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3): 14.2, 18.5, 55.3, 
55.9, 60.0, 101.6, 110.2, 111.4, 118.7, 136.5, 146.0, 148.9, 149.2, 153.6, 165.7. 
 
Ethyl 4-(benzo[d][1,3]dioxol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2-n): yield 81%; mp 188-190 ºC. 
1
H NMR (300 MHz, DMSO-d6): 1.11 (t, 3H, J 
7.0 Hz), 2.25 (s, 3H), 3.99 (q, 2H, J 7.0 Hz), 5.08 (d, 1H, J 2.6 Hz), 5.98 (s, 2H), 6.69-6.75 
(m, 2H), 6.84- 6.86 (m, 1H), 7.71 (br s, 1H, NH), 9.20 (br s, 1H, NH). 
13
C NMR (75 MHz, 
DMSO-d6): 14.1, 17.8, 53.7, 59.2, 99.3, 101.0, 106.7, 108.0, 119.4, 138.9, 146.4, 147.3, 
148.3, 152.1, 165.4. 
 
Ethyl 6-methyl-2-oxo-4-(thiophen-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2-p): 
yield 59%. 
1
H NMR (400 MHz, CDCl3): 1.17 (t, 3H, J 7.1 Hz), 2.23 (s, 3H), 4.07 (m, 2H), 
5.43 (s, 1H), 6.91 (m, 1H), 6.94 (m, 1H), 7.35 (m, 1H), 7.92 (br s, 1H, NH), 9.32 (br s, 1H, 
NH). 
13
C NMR (100 MHz, CDCl3): 14.6, 18.1, 49.8, 59.8, 100.3, 124.0, 125.1, 127.1, 149.1, 
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the title page and abstract followed by the main text, which must be structured into separate sections 
as Introduction, Materials and Methods, Conclusion, Conflict of interest, Acknowledgements and 
References. A “Highlight” is a brief review focused on recent progress on a topic of exceptional current 
interest and timeliness in the field. The Mini-Review Article should mention any previous important 
recent and old reviews in the field and contain a comprehensive discussion starting with the general 
background of the field. It should then go on to discuss the salient features of recent developments. The 
authors should avoid presenting material which has already been published in a previous review. The 
authors are advised to present and discuss their observations in brief. The manuscript style must be 
uniform throughout the text and 10 pt Times New Roman fonts should be used. The full term for an 
abbreviation should precede its first appearance in the text unless it is a standard unit of measurement. 
The reference numbers should be given in square brackets in the text. Italics should be used for Binomial 
names of organisms (Genus and Species), for emphasis and for unfamiliar words or phrases. Non-
assimilated words from Latin or other languages should also be italicized e.g. per se, et al. etc. 
SECTION HEADINGS: 
Section headings should be numbered sequentially, left aligned and have the first letter capitalized, 
starting with the introduction. Sub-section headings however, should be in lower-case and italicized with 
their initials capitalized. They should be numbered as 1.1, 1.2, etc. 
INTRODUCTION: 
The Introduction section should include the background and aims of the research in a comprehensive 
manner. 
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Bitmap images (e.g. screenshots) should not be converted to EPS as they result in a much larger file size 
than the equivalent JPEG, TIFF, PNG or BMP, and poor quality. EPS should only be used for images 
produced by vector-drawing applications such as Adobe Illustrator or CorelDraw. Most vector-drawing 
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